SCHEMBL5451008

SCHEMBL5451008

NC(=O)c1c(NC(=O)Oc2ccccc2)sc2c1CCOC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.59
CNR2 P34972 6/20 0.55
RAB7A P51149 1/20 0.52
PTPRC P08575 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPRB P23467 1/20 0.51
PTPRE P23469 1/20 0.51
CXCR2 P25025 3/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
FLT3 P36888 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CASP3 P42574 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
ANO1 Q5XXA6 3/20 0.47
CNR1 P21554 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467002 0.86 CFTR (0.59) CFTRCNR2RAB7ACXCR2FLT3
SCHEMBL5457809 0.82 MEN1 (0.55) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5455947 0.82 MEN1 (0.65) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5446002 0.81 PTPN1 (0.54) CFTRCNR2PTPN1NPC1RAB9A
SCHEMBL5449075 0.79 CFTR (0.66) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5453252 0.78 FLT3 (0.73) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5459985 0.78 CFTR (0.57) CFTRRAB7APTPRCPTPN2PTPN1
SCHEMBL5460547 0.78 MEN1 (0.58) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5444968 0.78 FLT3 (0.73) CFTRCNR2RAB7APTPRCPTPN2
SCHEMBL5453258 0.78 FLT3 (0.73) CFTRCNR2RAB7APTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885CNR2 2272/4885RAB7A 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.